GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividen ...

Medtronic (MDT) recently announced two major developments within its diabetes care business. The company received FDA approval for its Simplera continuous glucose monitor (CGM), which marks a significant step forward in diabetes management.Along with the FDA approval, Medtronic announced a global partnership with another MedTech stalwart, Abbott (ABT) . Considering the fact that the global diabetes care market has shown remarkable growth over the past few years, this partnership is expected to be strategica ...

In its upcoming report, Medtronic (MDT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $7.9 billion, representing a year-over-year increase of 2.5%.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its earni ...

ab 14 August 2024 Global Research and Evidence Lab Medtronic PLC Diabetes Turnaround Sustainable, Clearing Path to MSD Sales Growth; U/G to Neutral CGM Partnership Potentially Transformative for MDT Diabetes We are upgrading MDT to Neutral from Sell as we now have higher conviction that the recent Diabetes turnaround is sustainable. With Diabetes representing just under 10% of MDT's sales but also one of MDT's higher growth end markets, this business is critical to MDT's top-line growth trajectory. With thi ...

Medtronic (MDT) closed the most recent trading day at $82.27, moving +1.33% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1.69% for the day. At the same time, the Dow added 1.04%, and the tech-heavy Nasdaq gained 2.43%.Shares of the medical device company have appreciated by 5.33% over the course of the past month, outperforming the Medical sector's loss of 0.57% and the S&P 500's loss of 4.78%.The investment community will be closely monitoring the perfo ...

GALWAY, Ireland, Aug. 12, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2025 on Tuesday, August 20, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2025, which ended on Friday ...

PITTSBURGH, Aug. 9, 2024 /PRNewswire/ -- Federated Hermes, Inc. (NYSE: FHI), a global leader in active investing, today announced that the Board of Trustees of Federated Hermes ETF Trust, on behalf of its portfolio, Federated Hermes MDT Large Cap Growth ETF (NYSE: FLCG), has approved a change in the fundamental policy with respect to diversification, changing from a diversified company to a non-diversified company, subject to shareholder approval. The Board of Trustees also established Aug. 19, 2024, as the ...

Medtronic Diabetes expands CGM offerings to meet more people where they are in their diabetes journey DUBLIN, Aug. 7, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for its Simplera™ continuous glucose monitor (CGM) — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs. The discreet design simplifies the insertion and wear experience, eliminating the need ...

These two are rock-solid businesses with strong dividend programs.Every corporation will face challenges and setbacks -- which will sometimes sink its stock price. That's not a good reason for long-term investors to jump ship unless, of course, there's a fundamental shift in the company's prospects.Stocks that can perform reasonably well while maintaining a positive long-term outlook may well be worth holding onto for good. Corporations in this category are common, but they do exist; two examples are Merck ...

Shares of Medtronic (MDT) have been on a rough ride so far in 2024, replicating the overall medical device sector’s bearish trend, impacted by severe margin constraints. However, growing optimism surrounding the Fed’s approach toward an imminent rate cut comes as a relief for investors. On Jul 30, a day before the fifth interest rate decision of 2024 by the Federal Reserve, the stock finally broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.This is signifi ...